Mar 17, 2026 4:30pm EDT Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting
Feb 25, 2026 7:00am EST Immunocore reports fourth quarter and full year 2025 financial results and provides a business update
Feb 18, 2026 7:00am EST Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2026
Jan 09, 2026 7:00am EST Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference
Nov 07, 2025 8:00am EST Immunocore presents Phase 1 data for hepatitis B candidate at AASLD’s The Liver Meeting
Nov 06, 2025 7:00am EST Immunocore reports third quarter financial results and provides a business update
Aug 07, 2025 7:00am EDT Immunocore reports second quarter financial results and provides a business update
Jul 31, 2025 2:00am EDT Immunocore to report second quarter 2025 financial results and host call on August 7, 2025
May 07, 2025 7:00am EDT Immunocore reports first quarter financial results and provides a business update
Mar 10, 2025 3:00pm EDT Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025
Feb 26, 2025 7:00am EST Immunocore reports fourth quarter and full year 2024 financial results and provides a business update
Feb 19, 2025 7:00am EST Immunocore to report fourth quarter and full year 2024 financial results and host call on February 26, 2025
Jan 10, 2025 7:00am EST Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference
Jan 02, 2025 7:00am EST Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development
Dec 23, 2024 7:00am EST Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME
Dec 17, 2024 7:00am EST Immunocore announces dosing of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers
Dec 11, 2024 7:00am EST EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma
Dec 03, 2024 1:00am EST Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma
Nov 06, 2024 7:00am EST Immunocore reports third quarter financial results and provides a business update
Sep 14, 2024 3:00am EDT Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
Aug 08, 2024 7:00am EDT Immunocore reports second quarter financial results and provides a business update
Aug 01, 2024 7:00am EDT Immunocore to report second quarter 2024 financial results and host call on August 8, 2024
Jun 18, 2024 7:00am EDT Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
Jun 01, 2024 8:00am EDT Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
May 31, 2024 4:05pm EDT Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
May 29, 2024 7:00am EDT Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
May 08, 2024 7:00am EDT Immunocore reports first quarter financial results and provides a business update
Feb 28, 2024 7:34am EST Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
Feb 22, 2024 7:00am EST Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
Feb 21, 2024 7:00am EST Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024
Jan 05, 2024 7:00am EST Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
Nov 07, 2023 7:00am EST Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update
Nov 01, 2023 4:01pm EDT Immunocore announces upcoming poster presentations at SITC Annual Meeting 2023 and SMR Congress 2023
Oct 21, 2023 8:45am EDT Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial
Aug 10, 2023 7:00am EDT Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update
Aug 03, 2023 8:00am EDT Immunocore to report second quarter 2023 financial results and host call on August 10, 2023
Jun 03, 2023 7:00am EDT Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO
May 10, 2023 7:00am EDT Immunocore Reports First Quarter 2023 Financial Results and Provides Business Update
May 03, 2023 4:30pm EDT Immunocore to present at the Bank of America Securities 2023 Health Care Conference
Apr 18, 2023 7:00am EDT Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival
Apr 11, 2023 7:00am EDT Immunocore to present at the 22nd Annual Needham Virtual Healthcare Conference
Feb 23, 2023 7:00am EST Immunocore to Report Fourth Quarter and Full Year 2022 Earnings and Host Call on March 1, 2023
Feb 22, 2023 7:00am EST Immunocore announces initial Phase 1 safety and pharmacodynamic activity data with first soluble TCR therapy for people living with HIV
Jan 09, 2023 7:00am EST Immunocore announces strategic priorities including pipeline expansion for 2023 -2024
Dec 08, 2022 6:30am EST Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4
Dec 02, 2022 7:30am EST Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors
Nov 11, 2022 9:00am EST Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting
Nov 09, 2022 7:00am EST Immunocore Reports Third Quarter 2022 Financial Results and Provides Business Update
Sep 09, 2022 10:00am EDT Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress
Aug 10, 2022 7:00am EDT Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update
Aug 03, 2022 7:00am EDT Immunocore to Report Second Quarter 2022 Earnings and Host Call on August 10, 2022
Aug 01, 2022 7:00am EDT Immunocore announces upcoming oral presentation of initial Phase 1 data of ImmTAC® candidate IMC-F106C targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022
Jun 25, 2022 4:00am EDT Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™
Jun 08, 2022 7:00am EDT The UK Medicines and Healthcare products Regulatory Agency (MHRA), Australian Therapeutic Goods Administration (TGA) and Health Canada approve KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
Jun 06, 2022 7:00am EDT Immunocore presents new data on KIMMTRAK (tebentafusp-tebn) in metastatic cutaneous (mCM) and uveal melanoma (mUM) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Jun 03, 2022 7:00am EDT Immunocore announces clinical trial collaboration with Sanofi to evaluate Sanofi’s product candidate SAR444245, non-alpha IL-2, in combination with KIMMTRAK® in patients with metastatic cutaneous melanoma
May 26, 2022 6:00pm EDT Immunocore announces upcoming presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
May 11, 2022 7:00am EDT Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update
Apr 04, 2022 7:00am EDT European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
Mar 03, 2022 7:00am EST Immunocore Reports Full Year 2021 Financial Results and Provides Business Update
Feb 25, 2022 2:00am EST Immunocore receives positive CHMP opinion for KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma